311 related articles for article (PubMed ID: 18611186)
1. [In vitro drug sensitivity profiling in melanoma].
Ugurel S
J Dtsch Dermatol Ges; 2008 Jul; 6(7):611. PubMed ID: 18611186
[No Abstract] [Full Text] [Related]
2. What can we learn from phase II adjuvant trials in melanoma?
Keilholz U; Suciu S; Eggermont AM
Br J Cancer; 2000 Jul; 83(1):6-7. PubMed ID: 10883660
[No Abstract] [Full Text] [Related]
3. Biochemotherapy for melanoma: rational therapeutics in the search for weapons of melanoma destruction.
Margolin KA
Cancer; 2004 Aug; 101(3):435-8. PubMed ID: 15274056
[No Abstract] [Full Text] [Related]
4. Reactive oxygen species may have antitumor activity in metastatic melanoma.
Tuma RS
J Natl Cancer Inst; 2008 Jan; 100(1):11-2. PubMed ID: 18159075
[No Abstract] [Full Text] [Related]
5. Adjuvant therapy of cutaneous melanoma -- current status.
Hansson J
Acta Oncol; 2006; 45(4):369-72. PubMed ID: 16760171
[No Abstract] [Full Text] [Related]
6. Chemotherapy and chemoimmunotherapy for metastatic malignant melanoma: review and recent advances.
Khayat D; Coeffic D
Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():238-47. PubMed ID: 10895160
[No Abstract] [Full Text] [Related]
7. [Adjuvant drug therapy of malignant melanoma. Current knowledge and multi-center studies in German-speaking countries].
Hauschild A; Volkenandt M; Garbe C
Dtsch Med Wochenschr; 2000 Oct; 125(42):1272-8. PubMed ID: 11098240
[No Abstract] [Full Text] [Related]
8. LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951).
Agarwala SS; Keilholz U; Gilles E; Bedikian AY; Wu J; Kay R; Stein CA; Itri LM; Suciu S; Eggermont AM
Eur J Cancer; 2009 Jul; 45(10):1807-14. PubMed ID: 19419855
[TBL] [Abstract][Full Text] [Related]
9. Combination chemotherapy with dacarbazine and vindesine in the treatment of metastatic malignant melanoma.
Vorobiof DA; Sarli R; Falkson G
Cancer Treat Rep; 1986 Jul; 70(7):927-8. PubMed ID: 3719588
[No Abstract] [Full Text] [Related]
10. [New hope in metastatic melanoma treatment?].
Guillot B
Ann Dermatol Venereol; 2012 Oct; 139(10):693-4. PubMed ID: 23122388
[No Abstract] [Full Text] [Related]
11. Phase II trial of dacarbazine and thalidomide for the treatment of metastatic melanoma.
Ott PA; Chang JL; Oratz R; Jones A; Farrell K; Muggia F; Pavlick AC
Chemotherapy; 2009; 55(4):221-7. PubMed ID: 19451711
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy for metastatic melanoma.
Mandarà M; Nortilli R; Sava T; Cetto GL
Expert Rev Anticancer Ther; 2006 Jan; 6(1):121-30. PubMed ID: 16375649
[TBL] [Abstract][Full Text] [Related]
13. Treatments for metastatic melanoma: synthesis of evidence from randomized trials.
Lui P; Cashin R; Machado M; Hemels M; Corey-Lisle PK; Einarson TR
Cancer Treat Rev; 2007 Dec; 33(8):665-80. PubMed ID: 17919823
[TBL] [Abstract][Full Text] [Related]
14. Systemic chemotherapy.
Klimek VM; Wolchok JD; Chapman PB; Houghton AN; Hwu WJ
Clin Plast Surg; 2000 Jul; 27(3):451-61, ix-x. PubMed ID: 10941565
[TBL] [Abstract][Full Text] [Related]
15. [Chemotherapy of malignant melanoma].
Karakousis CP
Chirurg; 1986 Oct; 57(10):606-11. PubMed ID: 3792110
[No Abstract] [Full Text] [Related]
16. Cutaneous melanoma: available therapy for metastatic disease.
Tarhini AA; Agarwala SS
Dermatol Ther; 2006; 19(1):19-25. PubMed ID: 16405566
[TBL] [Abstract][Full Text] [Related]
17. A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha(v)beta(3), + or - dacarbazine in patients with stage IV metastatic melanoma.
Hersey P; Sosman J; O'Day S; Richards J; Bedikian A; Gonzalez R; Sharfman W; Weber R; Logan T; Buzoianu M; Hammershaimb L; Kirkwood JM;
Cancer; 2010 Mar; 116(6):1526-34. PubMed ID: 20108344
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant interferon therapy for melanoma.
Hancock B; Wheatley K; Ives N; Gore M
J Clin Oncol; 2005 Apr; 23(10):2431; author reply 2431-2. PubMed ID: 15800339
[No Abstract] [Full Text] [Related]
19. Systemic therapy for unresectable metastatic melanoma: impact of biochemotherapy on long-term survival.
Bedikian AY; Johnson MM; Warneke CL; McIntyre S; Papadopoulos N; Hwu WJ; Kim K; Hwu P
J Immunotoxicol; 2008 Apr; 5(2):201-7. PubMed ID: 18569391
[TBL] [Abstract][Full Text] [Related]
20. Discontinuation of melanoma combination immunotherapy.
Baker H
Lancet Oncol; 2017 Oct; 18(10):e565. PubMed ID: 28870612
[No Abstract] [Full Text] [Related]
[Next] [New Search]
